16 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 26 Phase 2, 6 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 16, Active not recruiting 3, Recruiting 2, Terminated 2, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 5, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow BCG: new trials by email Literature Review of BCG trials Research Report on BCG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia Bacillus Calmette Guerin Vaccine, Saline Injection - Fibromyalgia | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2024-11-21 | |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer N-803 and BCG, N-803 and Gemcitabine - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2025-11-01 | 2025-10-16 |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) Intismeran autogene, BCG - Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 308 | 2025-03-11 | 2026-10-01 |
| Evaluating the Safety and Immunogenicity of MTBVAC MTBVAC, BCG - HIV I Infection, Tuberculosis | Phase 2 | Recruiting | HIV Vaccine Trials Network | 276 | 2024-01-30 | 2026-10-30 |
| Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer Disitamab vedotin, Bacillus Calmette Guerin Vaccine - Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression | Phase 2 | Active not recruiting | Fudan University | 20 | 2023-12-18 | 2026-07-20 |
| Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years Bacillus Calmette-Guérin, Saline Injection - Diabetes Mellitus, Type 1 Diabetes | Phase 2 | Active not recruiting | Massachusetts General Hospital | 100 | 2023-05-04 | 2026-06-26 |
| A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD Biological/Vaccine: Bacillus Calmette-Guerin (BCG) - Mild Cognitive Impairment, Mild Dementia | Phase 2 | Completed | Steven E Arnold, MD | 15 | 2022-03-25 | 2025-04-13 |
| Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes Bacillus Calmette-Guérin, Saline Injection - Diabetes Mellitus, Type 1, Diabetes type1 | Phase 2 | Active not recruiting | Massachusetts General Hospital | 150 | 2022-03-22 | 2026-06-26 |
| Propranolol Adjuvant Treatment of Bladder Cancer Propranolol Hydrochloride, BCG - Bladder Cancer | Phase 2 | Unknown | Central South University | 242 | 2020-09-06 | 2020-07-30 |
| EMaBS TB Vaccine Study ChAdOx185A, MVA85A, BCG - Safety, Immunogenicity | Phase 1 / Phase 2 | Completed | University of Oxford | 72 | 2019-07-01 | 2022-08-05 |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer Avelumab, BCG - Bladder Cancer | Phase 1 / Phase 2 | Completed | University of Oklahoma | 18 | 2019-05-01 | 2024-02-14 |
| Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates MTBVAC, BCG - Tuberculosis | Phase 2 | Completed | Biofabri, S.L | 99 | 2019-02-12 | 2025-04-27 |
| A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder Nivolumab, BCG, BMS-986205 - Urinary Bladder Neoplasms | Phase 2 | Terminated | Bristol-Myers Squibb | 142 | 2018-08-02 | 2023-06-01 |
| MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa MTBVAC, BCG - Tuberculosis | Phase 1 / Phase 2 | Completed | International AIDS Vaccine Initiative | 144 | 2018-05-14 | 2023-02-27 |
| Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults MTBVAC, BCG - Tuberculosis | Phase 1 / Phase 2 | Completed | Biofabri, S.L | 54 | 2015-09-01 | 2018-05-01 |
| Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa VPM1002, BCG, VPM1002(Hyg+) - Tuberculosis | Phase 2 | Completed | Serum Institute of India Pvt. Ltd. | 416 | 2015-06-01 | 2018-04-18 |
| Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65 5μg/ml ESAT6-CFP10, 10μg/ml ESAT6-CFP10, BCG - Tuberculosis | Phase 2 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 1044 | 2015-03-01 | 2017-03-17 |
| Effects of BCG on Influenza Induced Immune Response Placebo, BCG - Influenza Virus Infection, Trained Immunity | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 40 | 2014-05-01 | 2015-11-10 |
| Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents AERAS-404, Placebo, Bacillus Calmette-Guérin (BCG) - Tuberculosis | Phase 2 | Completed | Aeras | 989 | 2014-02-01 | 2019-09-04 |
| A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT HS-410, Placebo, BCG - Bladder Cancer | Phase 1 / Phase 2 | Terminated | Heat Biologics | 104 | 2013-12-01 | 2020-02-17 |
Showing 20 of 26. Sign in to see all of them.
Tuberculosis (9) · Urinary Bladder Neoplasms (6) · Non-Muscle Invasive Bladder Neoplasms (5) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 1 (2) · Alzheimer Disease (1) · Carcinoma in Situ (1) · Cognitive Dysfunction (1) · Fibromyalgia (1) · HIV Infections (1) · Hypersensitivity (1) · Influenza, Human (1) · Malaria (1) · Malaria, Falciparum (1) · Neoplasms (1)
Massachusetts General Hospital (3) · Biofabri, S.L (2) · Aeras (1) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1) · Bristol-Myers Squibb (1) · Central South University (1) · Fudan University (1) · GlaxoSmithKline (1) · HIV Vaccine Trials Network (1) · Heat Biologics (1) · ImmunityBio, Inc. (1) · International AIDS Vaccine Initiative (1) · London School of Hygiene and Tropical Medicine (1) · Merck Sharp & Dohme LLC (1) · Radboud University Medical Center (1)
United States (8) · South Africa (7) · United Kingdom (4) · China (3) · Italy (3) · Netherlands (3) · Argentina (2) · Australia (2) · Brazil (2) · Canada (2) · Chile (2) · France (2) · Malawi (2) · Spain (2) · Colombia (1)
Denise L Faustman, MD, PhD (2) · Michele Tameris, MD (2) · Angelique Luabeya, MD (1) · Dingwei Ye (1) · Gary Steinberg, MD (1) · Heather B Jaspan, MD, PHD (1) · Helen McShane, Professor (1) · Kelly Stratton, MD (1) · Limakatso Lebina (1) · Mark Cotton, MD, Professor (1) · Mark Hatherill (1) · Mark Hatherill, MD (1)
PMID 25108027, PMID 25123116, PMID 26048780, PMID 26259542, PMID 27974398, PMID 28405623, PMID 29432383, PMID 29996082, PMID 31416768, PMID 34021314, PMID 35772447, PMID 40101388, PMID 42393277, PMID 42648772
2017 (1)